1-5 of 5
Daniel L. Gustafson
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

First-in-Class Inhibitors of Oncogenic CHD1L with Preclinical Activity against Colorectal Cancer

Joshua M. Abbott, Qiong Zhou, Hector Esquer, Laura Pike, Travis P. Broneske, Sébastien Rinaldetti, Adedoyin D. Abraham, Dominique A. Ramirez, Paul J. Lunghofer, Todd M. Pitts, Daniel P. Regan, Aik Choon Tan, Daniel L. Gustafson, Wells A. Messersmith, Daniel V. LaBarbera
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2020) 19 (8): 1598–1612.
https://doi.org/10.1158/1535-7163.MCT-20-0106
Published: 04 August 2020
View article titled, First-in-Class Inhibitors of Oncogenic CHD1L with Preclinical Activity against Colorectal Cancer
Open the PDF for First-in-Class Inhibitors of Oncogenic CHD1L with Preclinical Activity against Colorectal Cancer in another window
Includes: Supplementary data
Journal Articles

Identifying Candidate Druggable Targets in Canine Cancer Cell Lines Using Whole-Exome Sequencing

Sunetra Das, Rupa Idate, Kathryn E. Cronise, Daniel L. Gustafson, Dawn L. Duval
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (8): 1460–1471.
https://doi.org/10.1158/1535-7163.MCT-18-1346
Published: 01 August 2019
View article titled, Identifying Candidate Druggable Targets in Canine Cancer Cell Lines Using Whole-Exome Sequencing
Open the PDF for Identifying Candidate Druggable Targets in Canine Cancer Cell Lines Using Whole-Exome Sequencing in another window
Includes: Supplementary data
Journal Articles

Abstract A083: A phase Ib study of the combination of MLN0128 (dual TORC1/2 inhibitor) and MLN8237 (Aurora A inhibitor, alisertib) in patients with advanced solid tumors

S. Lindsey Davis, Elaine T. Lam, Bradley R. Corr, Cindy L. O'Bryant, Ashley Glode, Nichole Adler, Todd M. Pitts, John J. Tentler, Anna Capasso, Kyrie Dailey, Natalie J. Serkova, Colin D. Weekes, Daniel L. Gustafson, Christopher H. Lieu, Wells A. Messersmith, Stephen Leong, S. Gail Eckhardt, Jennifer R. Diamond
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (1_Supplement): A083.
https://doi.org/10.1158/1535-7163.TARG-17-A083
Published: 01 January 2018
View article titled, Abstract A083: A phase Ib study of the combination of MLN0128 (dual TORC1/2 inhibitor) and MLN8237 (Aurora A inhibitor, alisertib) in patients with advanced solid tumors
Journal Articles

A phase I study of gefitinib, capecitabine, and celecoxib in patients with advanced solid tumors

Elaine T. Lam, Cindy L. O'Bryant, Michele Basche, Daniel L. Gustafson, Natalie Serkova, Anna Baron, Scott N. Holden, Janet Dancey, S. Gail Eckhardt, Lia Gore
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2008) 7 (12): 3685–3694.
https://doi.org/10.1158/1535-7163.MCT-08-0436
Published: 15 December 2008
View article titled, A phase I study of gefitinib, capecitabine, and celecoxib in patients with advanced solid tumors
Open the PDF for A phase I study of gefitinib, capecitabine, and celecoxib in patients with advanced solid tumors in another window
Journal Articles

Pharmacokinetic-directed dosing of vandetanib and docetaxel in a mouse model of human squamous cell carcinoma

Erica L. Bradshaw-Pierce, Courtney A. Steinhauer, David Raben, Daniel L. Gustafson
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2008) 7 (9): 3006–3017.
https://doi.org/10.1158/1535-7163.MCT-08-0370
Published: 11 September 2008
View article titled, Pharmacokinetic-directed dosing of vandetanib and docetaxel in a mouse model of human squamous cell carcinoma
Open the PDF for Pharmacokinetic-directed dosing of vandetanib and docetaxel in a mouse model of human squamous cell carcinoma in another window
Includes: Supplementary data